Efavirenz pharmacogenetics in a cohort of Italian patients

International Journal of Antimicrobial Agents

Volumn 47, Issue 2, 2016, Pages 117-123

  Cusato, Jessica ^a   Tomasello, Cristina ^a,b   Simiele, Marco ^a,c   Calcagno, Andrea ^a   Bonora, Stefano ^a   Marinaro, Letizia ^a   Leggieri, Anna ^b   Allegra, Sarah ^a   Di Perri, Giovanni ^a   D'Avolio, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MARIA VITTORIA HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

ABCB1; CYP2B6; HNF4 ; Pharmacokinetics; SNP

Indexed keywords

CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; EFAVIRENZ; GLUCURONOSYLTRANSFERASE 2B7; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; PREGNANE X RECEPTOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ABCB1 GENE; ADULT; ARTICLE; BLOOD SAMPLING; CAUCASIAN; COHORT ANALYSIS; CYP2A6 GENE; CYP2B6 GENE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HNF4ALPHA GENE; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; MRP2 GENE; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; NR1I2 GENE; NR1I3 GENE; PHARMACOGENETICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; UGT2B7 GENE; CHEMISTRY; HUMAN IMMUNODEFICIENCY VIRUS 1; ITALY; MIDDLE AGED; PLASMA; POLYMERASE CHAIN REACTION;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; FEMALE; HIV-1; HUMANS; ITALY; MALE; MIDDLE AGED; PHARMACOGENETICS; PLASMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 84956956483     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.11.012     Document Type: Article

References (31)

1. A. Antinori, S. Marcotullio, A. Ammassari, M. Andreoni, G. Angarano, G. Carosi, and et al. Italian HIV Guidelines Working Group. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons New Microbiol 34 2011 109 146
2. M. Nelson, D. Dockrell, S. Edwards, B. Angus, S. Barton, N. Beeching, and et al. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011 HIV Med 12 Suppl 2 2011 1 140
3. C. Csajka, C. Marzolini, K. Fattinger, L.A. Decosterd, J. Fellay, A. Telenti, and et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection Clin Pharmacol Ther 73 2003 20 30
4. L. Ståhle, L. Moberg, J.O. Svensson, and A. Sönnerborg Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects Ther Drug Monit 26 2004 267 270
5. C. Marzolini, A. Telenti, L.A. Decosterd, G. Greub, J. Biollaz, and T. Buclin Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients AIDS 15 2001 71 75
6. T. Lang, K. Klein, J. Fischer, A.K. Nussler, P. Neuhaus, U. Hofmann, and et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver Pharmacogenetics 11 2001 399 415
7. Erratum in: Pharmacogenetics 2001;11:643
8. A.S. Belanger, P. Caron, M. Harvey, P.A. Zimmerman, R.K. Mehlotra, and C. Guillemette Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine Drug Metab Dispos 37 2009 1793 1796
9. A. Telenti, and U.M. Zanger Pharmacogenetics of anti-HIV drugs Annu Rev Pharmacol Toxicol 48 2008 227 256
10. C. Xu, S.K. Quinney, Y. Guo, S.D. Hall, L. Li, and Z. Desta CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based modeling Drug Metab Dispos 41 2013 2004 2011
11. C. Sukasem, T.R. Cressey, P. Prapaithong, Y. Tawon, E. Pasomsub, C. Srichunrusami, and et al. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults Br J Clin Pharmacol 74 2012 1005 1012
12. D. Burger, I. van der Heiden, C. la Porte, M. van der Ende, P. Groeneveld, C. Richter, and et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism Br J Clin Pharmacol 61 2006 148 154
13. A. D'Avolio Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of efavirenz (EFV) 11th international workshop on clinical pharmacology of HIV therapy 7-9 April, Sorrento, Italy 2010
14. M. Swart, Y. Ren, P. Smith, and C. Dandara ABCB1 4036A>G and 1236C>T polymorphisms affect plasma efavirenz levels in South African HIV/AIDS patients Front Genet 3 2012 236
15. E. Stormer, L.L. von Moltke, M.D. Perloff, and D.J. Greenblatt Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture Pharm Res 19 2002 1038 1045
16. A. Kwara, M. Lartey, K.W. Sagoe, N.L. Rzek, and M.H. Court CYP2B6 (c.516G→T) and CYP2A6 (∗9B and/or∗17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients Br J Clin Pharmacol 67 2009 427 436
17. J. di Iulio, A. Fayet, M. Arab-Alameddine, M. Rotger, R. Lubomirov, M. Cavassini, and et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function Pharmacogenet Genomics 19 2009 300 309
18. A. Kwara, M. Lartey, K.W. Sagoe, E. Kenu, and M.H. Court CYP2B6CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients AIDS 23 2009 2101 2106
19. C.C.A. Cortes, A. Owen, G. Zhang, and C. La Porte Correlates of efavirenz exposure in HIV infected patients from Chile reveals novel associations with a polymorphism in the constitutive androstane receptor and smoking 10th international workshop on clinical pharmacology of HIV therapy 15-17 April, Amsterdam, The Netherlands 2009 [abstract P-04 10]
20. C. Wyen, H. Hendra, M. Siccardi, M. Platten, H. Jaeger, T. Harrer, and et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens J Antimicrob Chemother 66 2011 2092 2098
21. A. D'Avolio, L. Baietto, M. Siccardi, M. Sciandra, M. Simiele, V. Oddone, and et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients Ther Drug Monit 30 2008 662 669
22. T.W. Mahungu, M.A. Johnson, A. Owen, and D.J. Back The impact of pharmacogenetics on HIV therapy Int J STD AIDS 20 2009 145 151
23. A. Owen, M. Pirmohamed, S.H. Khoo, and D.J. Back Pharmacogenetics of HIV therapy Pharmacogenet Genomics 16 2006 693 703
24. A. Calcagno, A. D'Avolio, M. Simiele, J. Cusato, R. Rostagno, V. Libanore, and et al. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices Br J Clin Pharmacol 74 2012 134 140
25. O. Janneh, B. Chandler, R. Hartkoorn, W.S. Kwan, C. Jenkinson, S. Evans, and et al. Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes J Antimicrob Chemother 64 2009 1002 1007
26. R. Winzer, P. Langmann, M. Zilly, F. Tollmann, J. Schubert, H. Klinker, and et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment Eur J Med Res 8 2003 531 534
27. S.G. Heil, M.E. van der Ende, P.W. Schenk, I. van der Heiden, J. Lindemans, D. Burger, and et al. Associations between ABCB1CYP2A6CYP2B6CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals Ther Drug Monit 34 2012 153 159
28. M. Arab-Alameddine, J. Di Iulio, T. Buclin, M. Rotger, R. Lubomirov, M. Cavassini, and et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals Clin Pharmacol Ther 85 2009 485 494
29. L. Bousquet, A. Pruvost, A.C. Guyot, R. Farinotti, and A. Mabondzo Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation Antimicrob Agents Chemother 53 2009 896 902
30. R. Puls, J. Amin, M. Losso, P. Phanuphak, C. Nwizu, C. Orrell, and et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial Lancet 383 2014 1474 1482
31. D.W. Haas, L.M. Smeaton, R.W. Shafer, G.K. Robbins, G.D. Morse, L. Labbe, and et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study J Infect Dis 192 2005 1931 1942